What Angel pharmaceutical does

Angel Pharmaceutical (和剂药业) is a privately held, clinical-stage biopharmaceutical company founded in October 2020 as a strategic joint venture with Nasdaq-listed Corvus Pharmaceuticals (CRVS), which holds a 49% equity stake. The company is headquartered in Jiaxing, Zhejiang, and operates dual R&D centers in Jiaxing (3,000+ sqm) and Burlingame, California (1,000+ sqm), with additional offices in Beijing and Shanghai; it runs a lean 11–50 employee organization with a PhD-heavy discovery and clinical development team. Its stated mission is to develop first-in-class and best-in-class innovative drugs for oncology and autoimmune diseases and make them accessible to Chinese patients.

The company's pipeline comprises five assets spanning immunotherapy mechanisms: CPI-818/soquelitinib (a global first-in-class oral ITK inhibitor with FDA Phase 3 approval for relapsed/refractory PTCL and NMPA clinical trial approval for atopic dermatitis), CPI-006/mupadolimab (a humanized anti-CD73 monoclonal antibody in Phase 1b/2 for solid tumors in China), ANG-0623 (a third-generation, highly selective BTK inhibitor with strong blood-brain barrier penetration, holding US and China Phase 1 clearance for multiple sclerosis), Ciforadenant/CPI-444 (an oral adenosine A2A receptor antagonist in development for renal cell carcinoma and multiple myeloma), and a preclinical PARP7 inhibitor with a filed patent. Angel holds Greater China rights for the three Corvus-licensed clinical-stage assets and global patent and commercial rights for the next-generation BTK inhibitor.

The business model is a dual-engine combination of in-licensed assets (from Corvus) and internal discovery, with revenue expected from future drug commercialization in China upon regulatory approval via licensing and royalties. The current go-to-market motion is enterprise clinical development: Angel operates clinical trials through top-tier Chinese hospital collaborations (Shanghai Dermatology Hospital, Peking University Cancer Hospital, Tongji University Affiliated East Hospital), recruits patients through trial centers, and is funded through equity rounds — a 280M RMB Series A in October 2020 (Betta Fund, Hisun Pharma, Tigermed, Rusheng Investment) and a $13.5M round in June 2026 led by Corvus Pharmaceuticals. The company is pre-revenue with no commercial products or disclosed pricing.

Name

Angel pharmaceutical

Legal name

嘉兴和剂药业有限公司 (Jiaxing Angel Pharmaceutical Co., Ltd.)

Website

https://angelpharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Angel Pharmaceutical is a pre-revenue, clinical-stage biopharmaceutical company developing first-in-class and best-in-class immuno-oncology and autoimmune drugs (ITK, CD73, BTK, A2A, PARP7 inhibitors) for the Chinese market, formed as a joint venture with Corvus Pharmaceuticals.

Ownership category

akta.pro rank

Headquarters

HQ city

Jiaxing

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company. Revenue is expected from future drug commercialization in China upon regulatory approval. The company holds Greater China rights for CPI-818, CPI-006, and CPI-444, and global patent rights for next-generation BTK inhibitor.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Angel Pharmaceutical is a clinical-stage biopharmaceutical company developing first-in-class and best-in-class innovative drugs for oncology and autoimmune diseases. Its pipeline includes an oral ITK inhibitor (CPI-818/Soquelitinib), a CD73 monoclonal antibody (CPI-006/Mupadolimab), a third-generation BTK inhibitor (ANG-0623), an adenosine A2A receptor antagonist (Ciforadenant/CPI-444), and a preclinical PARP7 inhibitor. The company leverages a dual-engine R&D model combining in-licensed clinical-stage assets from US partner Corvus Pharmaceuticals with proprietary in-house drug discovery across China and US R&D centers.

Product overview

Angel Pharmaceutical (和剂药业) is a clinical-stage innovative medicine company focused on oncology and autoimmune diseases. Its product portfolio comprises five pipeline candidates in various stages of clinical development: CPI-818 (Soquelitinib), an ITK inhibitor; CPI-006 (Mupadolimab), an anti-CD73 antibody; ANG-0623, a third-generation BTK inhibitor; Ciforadenant (CPI-444), an adenosine A2A receptor antagonist; and a PARP7 inhibitor in preclinical development. The company operates dual R&D centers in Jiaxing, China and Burlingame, California, USA, with rights to the Greater China region for three clinical-stage candidates from its strategic partner Corvus Pharmaceuticals, and global rights for its third-generation BTK inhibitor.

Differentiator

Problem solved

Functional benefit

Products and services

• CPI-818 (Soquelitinib) Global first-in-class oral selective small molecule ITK (interleukin-2 inducible T-cell kinase) inhibitor that modulates T-cell differentiation by inducing Th1 skewing and blocking Th2/Th17 cell development. Being developed for T-cell lymphomas, atopic dermatitis, and asthma; designed to prevent T-cell exhaustion and enhance cytotoxic T-cell production.
• CPI-006 (Mupadolimab) Humanized monoclonal antibody targeting CD73 with a unique mechanism for activating B-cells to produce immune responses against tumor antigens and viruses. Stimulates B-cells and blocks immunosuppressive adenosine production in the tumor microenvironment. Being developed for advanced solid tumors including non-small cell lung cancer.
• ANG-0623 (Next-Generation BTK Inhibitor) Highly selective third-generation BTK inhibitor with superior blood-brain barrier penetration compared to other BTK inhibitors in animal model studies, offering potential for primary CNS lymphomas and multiple sclerosis. Being developed for B-cell lymphomas and autoimmune diseases including multiple sclerosis.
• Ciforadenant (CPI-444) Oral small molecule adenosine A2A receptor antagonist that blocks the adenosine pathway in the tumor microenvironment, restoring immune cell cancer-killing properties. Includes adenosine gene signature biomarker for patient selection. Being developed for renal cell carcinoma and multiple myeloma.
• PARP7 Inhibitor PARP7 inhibitor in preclinical development that suppresses cancer cell growth and restores interferon signaling, activating T-cell mediated anti-tumor immunity. Demonstrated significant differentiation in preclinical animal models versus competing PARP7 inhibitors in clinical development.

Quantifiable outcome

• 75% of patients achieved EASI 75 (75% improvement in eczema area and severity index) in Phase 1 atopic dermatitis cohort 4 (highest dose)
• +4 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered flagship/ core, core and minor.

• Corvus Pharmaceuticalsflagship/ coreStrategic or Co-development Partner · 9 June 2026Corvus Pharmaceuticals co-founded Angel Pharmaceuticals in 2020 and holds a 49% equity stake. Corvus invested $5 million as part of a $13.5 million financing round in June 2026 to support clinical development of soquelitinib in China for atopic dermatitis and asthma. Angel holds Greater China rights for three clinical-stage pipeline drugs (CPI-818, CPI-006, CPI-444) and global patent/commercial rights for next-generation BTK inhibitor. The partnership enables Angel to leverage Corvus's clinical data and benefit from the Chinese inflammation and immunology markets.
• Peking University Cancer HospitalcoreStrategic or Co-development Partner · 7 November 2023Angel Pharmaceuticals has established comprehensive collaborations with Peking University Cancer Hospital in translational medicine and clinical research. The hospital's lymphoma department, led by Prof. Ding Ning, is involved in translational research on ITK inhibitor combination therapy mechanisms, and Prof. Song Yuqin leads the CPI-818 Phase 1b clinical trial in China.
• Tongji University Affiliated East HospitalcoreStrategic or Co-development Partner · 28 February 2023Tongji University Affiliated East Hospital serves as a clinical trial site for Angel Pharmaceuticals' CPI-006 (Mupadolimab) Phase 1b/1 trial in China for advanced solid tumors, led by Prof. Guo Ye (Deputy Director of Oncology Department and Secretary-General of CSCO).
• Guanhe Medical (观合医药)minorStrategic or Co-development Partner · 22 July 2021Angel Pharmaceuticals signed a strategic cooperation agreement with Guanhe Medical at the R&D center opening ceremony in July 2021, in addition to the Tigermed strategic agreement, to support clinical trial operations and development.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• AbbVie: Global biopharma that acquired Pharmacyclics (ibrutinib) for $21B and is therefore the institutional successor to Angel's co-founders' most successful prior work. Comparable as a major player in BTK and immunology markets where Angel's pipeline will compete or partner.
• BeiGene (now BeOne Medicines): Leading Chinese-founded global oncology biopharma with a broad innovative drug pipeline and approved BTK inhibitor zanubrutinib. Comparable as a China-headquartered developer of innovative oncology therapeutics competing for the same patient populations and capital pool.
• Innovent Biologics: Chinese biopharma with multiple approved innovative biologics (PD-1 sintilimab) and a broad pipeline spanning oncology and autoimmune diseases. Comparable as a China-based innovator commercializing novel immunology and immuno-oncology drugs.
• Junshi Biosciences: Chinese biopharma with approved PD-1 (toripalimab) and a broad pipeline in oncology and autoimmune diseases. Comparable as a clinical-to-commercial stage Chinese innovator with biologics and small molecule assets.

Emerging players

• Adagene: Clinical-stage Chinese-founded biotech developing antibody-based therapeutics for oncology. Comparable in clinical-stage innovative antibody drug development and China-US operational footprint.
• CStone Pharmaceuticals: Clinical-stage Chinese biopharma developing precision oncology and immuno-oncology therapeutics. Comparable in clinical-stage innovative drug development for oncology indications and similar partnership-driven model.
• Phanes Therapeutics: Clinical-stage Chinese biopharma developing innovative biologics and bispecific antibodies for oncology and autoimmune diseases. Comparable as a peer-sized Chinese innovator in clinical-stage immuno-oncology.

Direct peers

• HUTCHMED: Hong Kong-listed Chinese biopharma developing innovative small molecule kinase inhibitors and antibodies for oncology and autoimmune diseases. Closely comparable in clinical-stage development model, China-US presence, and oncology focus.
• Corvus Pharmaceuticals: Nasdaq-listed clinical-stage biopharma and Angel's 49% strategic shareholder. Corvus originated and develops the shared pipeline assets CPI-818 (soquelitinib), CPI-006 (mupadolimab), and CPI-444 (ciforadenant), making it the most direct operational and capital peer.
• Akeso, Inc. Chinese clinical-stage biopharma focused on immuno-oncology and autoimmune biologics including bispecific antibodies. Comparable in clinical-stage innovative drug development for oncology and autoimmune indications with China-US development footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angel pharmaceutical